Research progress on the molecular mechanism and related treatments of ferroptosis in osteosarcoma

doi:10.3760/cma.j.cn371439-20231229-00040

Abstract

Abstract:

Osteosarcoma is one of the most common primary malignant bone tumors， which has reached a "bottleneck" in the current clinical treatment of patients with osteosarcoma due to its poor prognosis and lack of therapeutic modalities. Recently， more and more researches have found that ferroptosis， as a novel cell death modality， may play an important role in osteosarcoma treatment. In recent years， with more in-depth studies on the mechanisms and molecular pathways related to ferroptosis， its specific therapeutic strategies in osteosarcoma have also been validated， which is expected to provide new ideas for the clinical treatment of osteosarcoma patients.

Key words: Osteosarcoma, Ferroptosis, Reactive oxygen species, Antineoplastic protocols

Wang Zihao, Wang Yu, Yang Xin, He Yi, Mo Xingkui, Yuan Tao. Research progress on the molecular mechanism and related treatments of ferroptosis in osteosarcoma[J]. Journal of International Oncology, 2024, 51(4): 239-244.

Figures/Tables 1

References 40

[1]	Lee JA, Lim J, Jin HY, et al. Osteosarcoma in adolescents and young adults[J]. Cells, 2021, 10(10): 2684. DOI: 10.3390/cells10102684.
[2]	Cole S, Gianferante DM, Zhu B, et al. Osteosarcoma: a surveillance, epidemiology, and end results program-based analysis from 1975 to 2017[J]. Cancer, 2022, 128(11): 2107-2118. DOI: 10.1002/cncr.34163.
[3]	Dos Santos AF, Fazeli G, Xavier da Silva TN, et al. Ferroptosis: mechanisms and implications for cancer development and therapy response[J]. Trends Cell Biol, 2023, 33(12): 1062-1076. DOI: 10.1016/j.tcb.2023.04.005.
[4]	Liu X, Du SW, Wang SD, et al. Ferroptosis in osteosarcoma: a promising future[J]. Front Oncol, 2022, 12: 1031779. DOI: 10. 3389/fonc.2022.1031779.
[5]	Lei T, Qian H, Lei PF, et al. Ferroptosis-related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma[J]. Cancer Sci, 2021, 112(11): 4785-4798. DOI: 10.1111/cas.15131.
[6]	Chen WK, Li ZG, Yu NC, et al. Bone-targeting exosome nanoparticles activate Keap1/Nrf2/GPX4 signaling pathway to induce ferroptosis in osteosarcoma cells[J]. J Nanobiotechnology, 2023, 21(1): 355. DOI: 10.1186/s12951-023-02129-1.
[7]	Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition[J]. Nature, 2017, 551(7679): 247-250. DOI: 10.1038/nature24297.
[8]	Rochette L, Dogon G, Rigal E, et al. Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis[J]. Int J Mol Sci, 2022, 24(1): 449. DOI: 10.3390/ijms24010449.
[9]	Guo WT, Wang X, Lu B, et al. Super-enhancer-driven MLX mediates redox balance maintenance via SLC7A11 in osteosarcoma[J]. Cell Death Dis, 2023, 14(7): 439. DOI: 10.1038/s41419-023-05966-y. pmid: 37460542
[10]	Nie JB, Ling YH, Jin MC, et al. Butyrate enhances erastin-induced ferroptosis of osteosarcoma cells via regulating ATF3/SLC7A11 pathway[J]. Eur J Pharmacol, 2023, 957: 176009. DOI: 10.1016/j.ejphar.2023.176009.
[11]	Liu Q, Wang KZ. The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin[J]. Cell Biol Int, 2019, 43(11): 1245-1256. DOI: 10.1002/cbin.11121. pmid: 30811078
[12]	Kirtonia A, Sethi G, Garg M. The multifaceted role of reactive oxygen species in tumorigenesis[J]. Cell Mol Life Sci, 2020, 77(22): 4459-4483. DOI: 10.1007/s00018-020-03536-5.
[13]	Gan BY. ACSL4, PUFA, and ferroptosis: new arsenal in anti-tumor immunity[J]. Signal Transduct Target Ther, 2022, 7(1): 128. DOI: 10.1038/s41392-022-01004-z.
[14]	Qiu C, Liu TY, Luo D, et al. Novel therapeutic savior for osteosarcoma: the endorsement of ferroptosis[J]. Front Oncol, 2022, 12: 746030. DOI: 10.3389/fonc.2022.746030.
[15]	Ge ZY, Song DL. A five ferroptosis-related genes risk score for prognostic prediction of osteosarcoma[J]. Medicine (Baltimore), 2022, 101(50): e32083. DOI: 10.1097/MD.0000000000032083.
[16]	Zhang YX, Li SY, Li FZ, et al. High-fat diet impairs ferroptosis and promotes cancer invasiveness via downregulating tumor suppressor ACSL4 in lung adenocarcinoma[J]. Biol Direct, 2021, 16(1): 10. DOI: 10.1186/s13062-021-00294-7. pmid: 34053456
[17]	Lee H, Zandkarimi F, Zhang YL, et al. Energy-stress-mediated AMPK activation inhibits ferroptosis[J]. Nat Cell Biol, 2020, 22(2): 225-234. DOI: 10.1038/s41556-020-0461-8. pmid: 32029897
[18]	Zhu YR, Zhang XY, Wu QP, et al. PF-06409577 activates AMPK signaling and inhibits osteosarcoma cell growth[J]. Front Oncol, 2021, 11: 659181. DOI: 10.3389/fonc.2021.659181.
[19]	Liu W, Zhao YC, Wang GF, et al. TRIM22 inhibits osteosarcoma progression through destabilizing Nrf2 and thus activation of ROS/AMPK/mTOR/autophagy signaling[J]. Redox Biol, 2022, 53: 102344. DOI: 10.1016/j.redox.2022.102344.
[20]	Wang DY, Wu YN, Huang JQ, et al. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance[J]. Chin J Cancer, 2016, 35: 47. DOI: 10.1186/s40880-016-0109-z.
[21]	Battaglia AM, Chirillo R, Aversa I, et al. Ferroptosis and cancer: mitochondria meet the "iron maiden" cell death[J]. Cells, 2020, 9(6): 32575749. DOI: 10.3390/cells9061505.
[22]	Han ST, Lin FY, Qi YC, et al. HO-1 contributes to luteolin-triggered ferroptosis in clear cell renal cell carcinoma via increasing the labile iron pool and promoting lipid peroxidation[J]. Oxid Med Cell Longev, 2022, 2022: 3846217. DOI: 10.1155/2022/3846217.
[23]	Li XJ, Liu JY. FANCD2 inhibits ferroptosis by regulating the JAK2/STAT3 pathway in osteosarcoma[J]. BMC Cancer, 2023, 23(1): 179. DOI: 10.1186/s12885-023-10626-7. pmid: 36814203
[24]	Bersuker K, Hendricks JM, Li ZP, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis[J]. Nature, 2019, 575(7784): 688-692. DOI: 10.1038/s41586-019-1705-2.
[25]	Kraft VAN, Bezjian CT, Pfeiffer S, et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling[J]. ACS Cent Sci, 2020, 6(1): 41-53. DOI: 10.1021/acscentsci.9b01063.
[26]	Mao C, Liu XG, Zhang YL, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer[J]. Nature, 2021, 593(7860): 586-590. DOI: 10.1038/s41586-021-03539-7.
[27]	Luo Y, Gao X, Zou LT, et al. Bavachin induces ferroptosis through the STAT3/P53/SLC7A11 axis in osteosarcoma cells[J]. Oxid Med Cell Longev, 2021, 2021: 1783485. DOI: 10.1155/2021/1783485.
[28]	Liu JY, Lou CG, Zhen CX, et al. Iron plays a role in sulfasalazine-induced ferroptosis with autophagic flux blockage in K7M2 osteosarcoma cells[J]. Metallomics, 2022, 14(5): mfac027. DOI: 10.1093/mtomcs/mfac027.
[29]	Lv HH, Zhen CX, Liu JY, et al. β-Phenethyl isothiocyanate induces cell death in human osteosarcoma through altering iron metabolism, disturbing the redox balance, and activating the MAPK signaling pathway[J]. Oxid Med Cell Longev, 2020, 2020: 5021983. DOI: 10.1155/2020/5021983.
[30]	Lv HH, Zhen CX, Liu JY, et al. PEITC triggers multiple forms of cell death by GSH-iron-ROS regulation in K7M2 murine osteosarcoma cells[J]. Acta Pharmacol Sin, 2020, 41(8): 1119-1132. DOI: 10.1038/s41401-020-0376-8.
[31]	Fan Q, Zhan XL, Xiao ZM, et al. Phenethyl isothiocyanate enhances adriamycin-induced apoptosis in osteosarcoma cells[J]. Mol Med Rep, 2015, 12(4): 5945-5950. DOI: 10.3892/mmr.2015.4187.
[32]	De Vico G, Martano M, Maiolino PL, et al. Expression of transferrin receptor-1 (TFR-1) in canine osteosarcomas[J]. Vet Med Sci, 2020, 6(3): 272-276. DOI: 10.1002/vms3.258. pmid: 32239803
[33]	Salaroli R, Andreani G, Bernardini C, et al. Anticancer activity of an Artemisia annua L. hydroalcoholic extract on canine osteosarcoma cell lines[J]. Res Vet Sci, 2022, 152: 476-484. DOI: 10.1016/j.rvsc.2022.09.012. pmid: 36156377
[34]	Chen M, Jiang YH, Sun YB. KDM4A-mediated histone demethy-lation of SLC7A11 inhibits cell ferroptosis in osteosarcoma[J]. Biochem Biophys Res Commun, 2021, 550: 77-83. DOI: 10.1016/j.bbrc.2021.02.137.
[35]	Xu WN, Yang RZ, Zheng HL, et al. NDUFA4L2 regulated by HIF-1α promotes metastasis and epithelial-mesenchymal transition of osteosarcoma cells through inhibiting ROS production[J]. Front Cell Dev Biol, 2020, 8: 515051. DOI: 10.3389/fcell.2020.515051.
[36]	马小平, 常君丽, 孙星媛, 等. 长非编码RNA调控骨肉瘤耐药机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 51-54. DOI: 10.3760/cma.j.cn371439-20221005-00010.
[37]	Liu YF, Zhang ZM, Li Q, et al. Mitochondrial APE1 promotes cisplatin resistance by downregulating ROS in osteosarcoma[J]. Oncol Rep, 2020, 44(2): 499-508. DOI: 10.3892/or.2020.7633. pmid: 32627008
[38]	Zhang YN, Shen GH, Meng TT, et al. Eicosapentaenoic acid enhances the sensitivity of osteosarcoma to cisplatin by inducing ferroptosis through the DNA-PKcs/AKT/NRF2 pathway and reducing PD-L1 expression to attenuate immune evasion[J]. Int Immunopharmacol, 2023, 125(Pt B): 111181. DOI: 10.1016/j.intimp.2023.111181.
[39]	Liu L, Geng H, Mei CJ, et al. Zoledronic acid enhanced the antitumor effect of cisplatin on orthotopic osteosarcoma by ROS-PI3K/Akt signaling and attenuated osteolysis[J]. Oxid Med Cell Longev, 2021, 2021: 6661534. DOI: 10.1155/2021/6661534.
[40]	Tang Z, Dong H, Li T, et al. The synergistic reducing drug resistance effect of cisplatin and ursolic acid on osteosarcoma through a multistep mechanism involving ferritinophagy[J]. Oxid Med Cell Longev, 2021, 2021: 5192271. DOI: 10.1155/2021/5192271.